Pharmaceuticals News and Research

RSS

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced positive results from a Phase I/II challenge study of its norovirus virus-like particle (VLP) vaccine candidate.

26 Oct 2010

Dual antiplatelet therapy study expanded into Australia and New Zealand

The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into Australia and New Zealand. Professor Ian Meredith, MBBS, Ph.D., interventional cardiologist at MonashHeart in Melbourne, Australia and National Coordinating Investigator for the DAPT Study in Australia, was the first Pacific Rim investigator to enroll patients into the study.

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

ATMI and Austar open new Chinese manufacturing facility

ATMI, Inc. today announced that it has further extended its global biopharma manufacturing footprint with the opening of a new Chinese manufacturing facility as part of a joint venture with Austar, a Hong Kong-based comprehensive service provider to the China pharmaceutical industry.

25 Oct 2010

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.

25 Oct 2010

DARA BioSciences to raise $1.4 million in registered direct offering

DARA BioSciences, Inc., a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with several institutional investors to sell 612,667 units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $1.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.

25 Oct 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

GSN initiates trial of microarray PGD on pregnancy and implantation rates in IVF

Gene Security Network (GSN) announced today that it has initiated enrollment for a prospective randomized trial in collaboration with Ferring Pharmaceuticals to evaluate the impact of GSN's advanced preimplantation genetic diagnosis (PGD) with Parental Support™ on pregnancy and implantation rates in IVF.

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Titan expects to receive royalty payment from Fanapt net sales

Titan Pharmaceuticals, Inc. today reported that the company expects to receive a royalty payment of approximately $395,000 on third quarter 2010 net sales of Fanapt (iloperidone) of approximately $4.9 million.

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Neptune launches Onemia medical food

Neptune Technologies & Bioressources Inc. enters the pharmaceutical market with the launch of Onemia™, the first medical food of Neptune's subsidiary Acasti Pharma Inc.. Only two years since its foundation, Acasti has completed the development and launch of "Onemia™" on October 21, 2010 at the Cardiometabolic Health Congress meeting in Boston.

25 Oct 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

25 Oct 2010

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy.

25 Oct 2010

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting.

25 Oct 2010

Pfizer subsidiary commences tender offer for King

Pfizer Inc. today announced the commencement of a tender offer by its wholly owned subsidiary, Parker Tennessee Corp., for all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

25 Oct 2010

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.

25 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

Pharmaceutical company Pharmaxis today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.

25 Oct 2010

Aegerion prices initial public offering of common stock

Aegerion Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share, before underwriting discounts and commissions.

25 Oct 2010

Pharmaceuticals News and Research

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

Dual antiplatelet therapy study expanded into Australia and New Zealand

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

ATMI and Austar open new Chinese manufacturing facility

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

DARA BioSciences to raise $1.4 million in registered direct offering

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

GSN initiates trial of microarray PGD on pregnancy and implantation rates in IVF

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Titan expects to receive royalty payment from Fanapt net sales

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

Neptune launches Onemia medical food

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Pfizer subsidiary commences tender offer for King

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

Aegerion prices initial public offering of common stock

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence